BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.15, $0.12 better than the analyst estimate of $0.03. Revenue for the quarter came in at $533.8 million versus the consensus estimate of $520.35 million.

GUIDANCE:

BioMarin Pharma sees FY2022 revenue of $2.06-2.16 billion, versus the consensus of $2.11 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.